India, Oct. 12 -- Shares of First Tracks Biotherapeutics (TRAX) gained over 9% on Monday after the company reported positive Phase 1b results for ANB033, demonstrating protection against gluten-induced intestinal damage and symptoms in patients with celiac disease.
The stock is currently trading at $34.77, up $2.92 or 9.16%, on the Nasdaq. It opened at $39.60 after closing the previous session at $31.85. The stock has traded between $14.72 and $49.91 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....